Navigation Links
Key pathway in end-stage prostate cancer tumor progression blocked

DALLAS July 22, 2010 Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.

The findings, appearing online and in the August issue of Endocrinology, suggest that this step might one day provide a new avenue of therapy for patients with end-stage prostate cancer. Health care experts estimate that more than 2 million men in the U.S. have prostate cancer, with more than 27,000 deaths related to the disease in 2009.

"We were able to block the androgen response, which is a central pathway for tumor progression," said Dr. Nima Sharifi, assistant professor of internal medicine and the study's senior author.

End-stage prostate tumors typically are treated with hormones that suppress the levels of the androgens, or male hormones like testosterone, that cause prostate cancer cells to grow. Eventually, however, the tumors become resistant to this therapy and resume their growth.

Using prostate cancer cell lines, Dr. Sharifi and his colleagues found that the hormone dehydroepiandrosterone (DHEA) is converted by the tumors into androgens. By blocking the enzyme 3β-hydroxysteroid dehydrogenase (3βHSD), which is responsible for the first enzymatic step that is required to convert DHEA to androgens, researchers were able to shut down the tumors' lifeline.

"Enzymes in general can make great drug targets, so this process conceivably could be targeted for the development of new treatments for end-stage prostate cancer, which has limited therapeutic options right now," said Dr. Sharifi, an investigator in UT Southwestern's Harold C. Simmons Comprehensive Cancer Center. "The goal would be to develop a drug that targets that enzyme to be used for the advanced, incurable stage."

No standard treatments currently target this enzyme, but there is proven clinical evidence that this pathway is central to driving tumor progression.


Contact: Connie Piloto
UT Southwestern Medical Center

Related medicine news :

1. Scientists find link between estrogen metabolism pathway and breast cancer risk
2. Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways
3. New pathway to cheap insulin
4. A single protein regulates 2 immune pathways
5. Space Coast Cancer Center Selects Via Oncology™ Pathways to Advance Evidence-Based Cancer Care
6. Targeting cell pathway may prevent relapse of leukemia
7. Newly identified proteins critical to FA pathway DNA repair function
8. Cellular pathway could provide evidence of how cancer and obesity are linked
9. Welsh Tree LLC Proudly Presents the Release of the Celtic Pathways CD by Jason Evans, in Time for Saint Patrick's Day
10. Different signaling pathways of cholangiocarcinoma
11. Arsenic exposure activates an oncogenic signaling pathway; leads to increased cancer risk
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s ... STEMI and Sepsis conditions present in similar ways and require time-critical intervention to avoid ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic ... the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 ... need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: